Month: April 2026

At the recent Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Professor Florent Malard from Sorbonne Université, lead of the Microbiome Research Project within the EBMT Cellular Therapy & Immunobiology Working Party, presented the final results of the ARES Phase III clinical trial. The presentation focused on the efficacy and safety of MAAT013, a novel microbiome-based therapeutic, for patients with ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD).

During the EBMT Annual Meeting, Dr. Francesca Ferrua from the IRCCS San Raffaele Scientific Institute presented an integrated analysis of the lentiviral hematopoietic stem and progenitor cell (HSPC) gene therapy, etuvetidigene autotemcel (ototemcel), for the treatment of Wiskott-Aldrich Syndrome (WAS). The report highlighted remarkable efficacy and safety outcomes with a follow-up period extending up to 13 years.

At the EBMT 2026 Annual Meeting, Professor Franco Locatelli from Bambino Gesù Children’s Hospital presented long-term follow-up data for exagamglogene autotemcel (exa-cel), a CRISPR/Cas9-based gene-editing therapy. The study included patients with transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). With a median follow-up of over three years and some patients reaching over six years, the results provide robust evidence for the long-term efficacy and safety of gene editing in hereditary blood disorders.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.

Iron deficiency anemia (IDA) is the most common nutritional deficiency and the leading cause of anemia worldwide. Despite the availability of well-established diagnostic methods, IDA is often underestimated in clinical practice as a “minor condition.”

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026, coinciding with the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.